Last reviewed 2026-05-31 · How we verify

Ceftezol (CEFTEZOLE)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 29/100

Ceftezol (generic name: CEFTEZOLE) is a ceftezole drug. It is currently in Phase 2 development.

Ceftezole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Ceftezol is a small molecule antibiotic. It is also known by the synonyms CEFTEZOL, CEFTEZOLE, and J01DB12.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CEFTEZOLE
Drug class	ceftezole
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine the bacterial cell wall as a brick wall. Ceftezole blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse, killing the bacteria. This process is crucial for the bacteria to survive and multiply.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ceftezol CI brief — competitive landscape report
Ceftezol updates RSS · CI watch RSS

Frequently asked questions about Ceftezol

What is Ceftezol?

Ceftezol (CEFTEZOLE) is a ceftezole drug.

How does Ceftezol work?

Ceftezole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

What is the generic name of Ceftezol?

CEFTEZOLE is the generic (nonproprietary) name of Ceftezol.

What drug class is Ceftezol in?

Ceftezol belongs to the ceftezole class. See all ceftezole drugs at /class/ceftezole.

What development phase is Ceftezol in?

Ceftezol is in Phase 2.

Drug class: All ceftezole drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing